ライフサイエンスコーパス: colon carcinoma

1 s as a suppressor of spontaneous sarcoma and colon carcinoma.

2 the colitic microenvironment and associated colon carcinoma.

3 o as a therapeutic target in models of human colon carcinoma.

4 NR) may have independent prognostic value in colon carcinoma.

5 pressed in human multiple myeloma as well as colon carcinoma.

6 ls contributes to the hematogenous spread of colon carcinoma.

7 pithelial to mesenchymal transition (EMT) of colon carcinoma.

8 rall survival (OS) after primary surgery for colon carcinoma.

9 tem cell self-renewal and is dysregulated in colon carcinoma.

10 mber of tumor entities such as pancreatic or colon carcinoma.

11 repeat genotyping to study the evolution of colon carcinoma.

12 mutations can be found in other cancers than colon carcinoma.

13 igen over 7 d using a syngeneic rat model of colon carcinoma.

14 also confirmed in mouse prostate cancer and colon carcinoma.

15 n IFN-alpha-driven tumor microenvironment in colon carcinoma.

16 xymethane and dextran sodium sulfate-induced colon carcinoma.

17 18)F-FLT uptake in arthritic ankles and CT26 colon carcinomas.

18 ay lead to improved therapeutic regimens for colon carcinomas.

19 of tumor growth in mice with implanted CT-26 colon carcinomas.

20 of microsatellite instability (MSI) in human colon carcinomas.

21 ar matrix surrounding tumor cells, including colon carcinomas.

22 brin, but not fibrinogen, receptor on LS174T colon carcinomas.

23 nous dissemination of tumor cells, including colon carcinomas.

24 dendrimer was evaluated in mice bearing C-26 colon carcinomas.

25 f antiangiogenesis in ectopic and orthotopic colon carcinomas.

26 ely correlated with PTEN expression in human colon carcinomas.

27 n several epithelial cancers, including many colon carcinomas.

28 drome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for f

29 MCF-7 (human breast carcinoma), HT-29 (human colon carcinoma), A2780 (human ovarian carcinoma), and A

30 We previously reported that colon carcinomas, adenomas, and hyperplastic polyps exhi

31 nude mice bearing subcutaneous LS 174T human colon carcinoma and C6 rat glioma tumors.

32 ct on mRNA levels in primary enterocytes and colon carcinoma and hepatoma cells.

33 D8(+) T effector cells in tumor models (CT26 colon carcinoma and ID8-VEGF ovarian carcinoma).

34 Another variant was identified in a colon carcinoma and is altered at position 289 from lysi

35 -dependent STAT3 activation in the T84 human colon carcinoma and Jurkat human T-cell leukemia lines.

36 been linked to many human cancers including colon carcinoma and melanoma.

37 sed expression of claudin-1 in human primary colon carcinoma and metastasis and in cell lines derived

38 cumulated on the lateral interfaces of human colon carcinoma and normal intestinal epithelial cells b

39 ion between MET and TNS4 expression in human colon carcinoma and ovarian carcinoma suggests TNS4 play

40 nism for how RhoC expression is regulated in colon carcinoma and substantiate its utility as a progno

41 models of human cancer, including LoVo human colon carcinoma and U87-MG human glioblastoma, when dose

42 show that USP39 is up-regulated in lung and colon carcinomas and its expression correlates with KRAS

43 Quinacrine induced apoptosis in colon carcinomas and potentiated the cytotoxic activity

44 p85beta expression is elevated in breast and colon carcinomas and that its increased expression corre

45 f ST6Gal-I occurs in many cancers, including colon carcinoma, and correlates with metastasis and poor

46 ciated with multiple malignancies, including colon carcinoma, and with ectodermal and mesoendodermal

47 adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of apc(mcr) mutan

48 oxygenase-2 (COX-2) is up-regulated in human colon carcinomas, and its inhibition is associated with

49 man lung carcinoma, Colo205 and LS174T human colon carcinomas, and U87MG human glioblastoma multiform

50 FET cells, derived from an early-stage colon carcinoma, are nontumorigenic in athymic mice.

51 are as effective in treating the murine C26 colon carcinoma as Doxil, a commercial liposome doxorubi

52 ranging from 0.05 to 2.45 muM against HT-29 colon carcinoma as well as MCF-7 and MDA-MB-231 mammary

53 antimetastatic activity in a murine model of colon carcinoma, as well as potent antiadhesive properti

54 We injected arthritic, healthy, and CT26 colon carcinoma-bearing mice with (18)F-FLT before stati

55 is by 10 wk post-infection, progressing into colon carcinoma by 20 wk post-infection, with pronounced

56 ained significant inhibitory effects against colon carcinoma (CaCo-2) cells.

57 ity and CaSR protein expression in the human colon carcinoma CBS cells, which possessed a functional

58 Moreover, CEA and CD44v cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin at el

59 ves have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT11

60 ncer cell cytotoxicity assays with the human colon carcinoma cell line (HT-29) showed that internaliz

61 ction of wild type APC into an APC-deficient colon carcinoma cell line (HT29) resulted in increased e

62 n largazole 1 in growth inhibition of HCT116 colon carcinoma cell line and in inducing increases in g

63 CT26 syngeneic beta-galactosidase-expressing colon carcinoma cell line and subsequently immunized wit

64 isense inhibition of SIM2-s in a RKO-derived colon carcinoma cell line causes growth inhibition, apop

65 We recently demonstrated that the LS174T colon carcinoma cell line expresses the CD44 glycoform k

66 We identified LSR splice variants in the colon carcinoma cell line HCT116 and disrupted the LSR g

67 ach to a study of gene expression in the RKO colon carcinoma cell line in response to varying dosage

68 tudies, and blot rolling assays of LS174T, a colon carcinoma cell line known to interact with E-selec

69 YAMC cells, the mouse colon carcinoma cell line MC38, the mouse macrophage cel

70 ominant MHC class I tumor antigen of a mouse colon carcinoma cell line stimulates a tumor-specific T-

71 x1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechan

72 Treatment of a human colon carcinoma cell line with alpha-DABA versus gamma-D

73 modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observati

74 inhibited cell growth of an aggressive human colon carcinoma cell line, FET6alphaS26X, which harbors

75 ation, apoptosis and cell cycle in the human colon carcinoma cell line, HT-29.

76 strong binding to the Caco-2 cells, a human colon carcinoma cell line.

77 iated cytotoxicity against Colo-205, a human colon carcinoma cell line.

78 unilaterally by the CT26 wild type (CT26WT) colon carcinoma cell line.

79 valuated in vitro using the HCT116/LUC human colon carcinoma cell line.

80 pathways controlled by p53, isogeneic human colon carcinoma cell lines (HCT116) differing only in th

81 tumorigenicity, and metastasis in Smad4-null colon carcinoma cell lines (MC38 and SW620) and in those

82 L-induced apoptosis in TRAIL-resistant human colon carcinoma cell lines (RKO, HT29, and HCT8).

83 th the adenoma and carcinomas samples, seven colon carcinoma cell lines also lacked expression of RDH

84 imulation were immunoprecipitated from human colon carcinoma cell lines and identified by mass spectr

85 e in murine liver and human HCC, breast, and colon carcinoma cell lines and specimens.

86 Thus, six of seven colon carcinoma cell lines from the NCI Anticancer Drug

87 -resistant and metastatic phenotype in human colon carcinoma cell lines in vitro.

88 We report MRN deficiency in three of seven colon carcinoma cell lines of the NCI Anticancer Drug Sc

89 id cells resulting from the culture of human colon carcinoma cell lines or primary mouse epithelial c

90 glycosylation profiles of the isogenic human colon carcinoma cell lines SW480 (primary tumor) and SW6

91 T61, was used to block HH signaling in human colon carcinoma cell lines that express HH signaling com

92 that interferon (IFN)-gamma sensitizes human colon carcinoma cell lines to the cytotoxic effects of 5

93 OCUS, Mahlavu liver, MCF7 breast, and HCT116 colon carcinoma cell lines.

94 enhanced motility and invasiveness of other colon carcinoma cell lines.

95 abolished the clonogenicity of all six human colon carcinoma cell lines.

96 e dependent on JMJD1A in both renal cell and colon carcinoma cell lines.

97 ve NF-kappaB activation in five of six human colon carcinoma cell lines; this activation is inhibited

98 t (CRMP-2L) alone binds ROCK II and inhibits colon carcinoma cell migration and invasion.

99 ST6Gal-I knockdown and forced overexpression colon carcinoma cell models, we find that alpha2-6 sialy

100 so known as ArhGEF28 or p190RhoGEF) promotes colon carcinoma cell motility and tumor progression via

101 h, structure-dependent toxicity to the human colon carcinoma cell-line HCT116 p53(++), causing dramat

102 Syngenic TWIST1-positive colon carcinoma cells (CT26) that invaded tissues surrou

103 In human colon carcinoma cells (HCT-8) and lung carcinoma cells (

104 is of intracellular Ca(2+) handling in human colon carcinoma cells (HT29) versus normal human mucosa

105 al transition (EMT) of highly differentiated colon carcinoma cells (LIM1863 cells).

106 e transfer in rat hepatocytes (WB) and human colon carcinoma cells (LoVo).

107 0 times less toxic than free DOX toward C-26 colon carcinoma cells after exposure for 72 h.

108 esis, we genetically engineered HCT116 human colon carcinoma cells and 4T1 mouse mammary carcinoma ce

109 These analogues inhibit LSD1 in human colon carcinoma cells and affect a reexpression of multi

110 the expression of CD44 and/or CEA in LS174T colon carcinoma cells and analyzed their ability to meta

111 s coated with CEA immunopurified from LS174T colon carcinoma cells and selectins as substrate reveal

112 ve, i.e. autophosphorylated, ErbB2 in HCT116 colon carcinoma cells and TA3/St mammary carcinoma cells

113 been shown to be active in human breast and colon carcinoma cells and to promote their invasion thro

114 tribute to aberrant COX-2 expression in HT29 colon carcinoma cells and to reveal the role of platelet

115 romoter of the p21 gene in unstressed HCT116 colon carcinoma cells are localized within a region of r

116 We found that Ca(2+) stores in colon carcinoma cells are partially depleted relative to

117 lity to these viruses and observed that HT29 colon carcinoma cells are susceptible to infection by ne

118 ose findings by showing that T84 and Colo205 colon carcinoma cells bind selectins via sialidase-sensi

119 of the R2 protein in p53(-/-) HCT-116 human colon carcinoma cells but induced degradation of the pro

120 Pdcd4 suppresses tumor progression in human colon carcinoma cells by the novel mechanism of down-reg

121 Basal CXCR4 promoter activity in HCT116 colon carcinoma cells deleted of p53 [HCT116(p53KO)] was

122 In DLD-1 colon carcinoma cells depleted of Galpha13, gastrin-indu

123 pin RNA (shRNA) knockdown of fascin in human colon carcinoma cells derived from an aggressive primary

124 treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and e

125 die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and par

126 Heparin diminishes the avidity of colon carcinoma cells for P- and L-selectin, which may c

127 is a key survival factor that protects human colon carcinoma cells from TNF-related apoptosis-inducin

128 mediated protection against either breast or colon carcinoma cells in prophylactic and therapeutic se

129 ance the cytotoxicity of these drugs against colon carcinoma cells in vitro demonstrating a clear syn

130 shown that ETS1 represses tumorigenicity of colon carcinoma cells in vivo, and that the p42-ETS1 pro

131 xpression is critical for tumor formation by colon carcinoma cells in vivo.

132 it proliferation, migration, and invasion of colon carcinoma cells indicating tumor suppressor activi

133 e show that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and C

134 Selection of irinotecan resistance in colon carcinoma cells led to a greater proportion of CSC

135 t variant isoforms of CD44 (CD44v) on LS174T colon carcinoma cells possess P-/L-/E-selectin binding a

136 that CD44 variant isoforms (CD44v) on LS174T colon carcinoma cells possess selectin binding activity.

137 tion of MAP1D expression by shRNA in HCT-116 colon carcinoma cells reduces anchorage-independant grow

138 y analysis of Pdcd4-overexpressing RKO human colon carcinoma cells revealed MAP4K1 as the sole target

139 In contrast, colon carcinoma cells showed mixed currents composed of

140 ic and metastatic profile in both breast and colon carcinoma cells than plasma from mice treated with

141 tected high levels of RhoA activity in HCA-7 colon carcinoma cells that constitutively express COX-2.

142 r, JW55 inhibited canonical Wnt signaling in colon carcinoma cells that contained mutations in either

143 formed mouse embryonic fibroblasts and HT-29 colon carcinoma cells that express a dominant negative P

144 gs, down-regulation of Hsp27 in HCT116 human colon carcinoma cells that express this heat shock prote

145 and alpha2beta1 integrins on the surface of colon carcinoma cells through the disintegrin domain.

146 S1 protein bypasses a defect in apoptosis in colon carcinoma cells through the up-regulation of caspa

147 ut enabled quiescent HD6, SW480, and colo320 colon carcinoma cells to acquire some biochemical charac

148 itro and in vivo Exposing human lymphoma and colon carcinoma cells to AZD3965 increased MCT4-dependen

149 Serum starvation induced HD6 colon carcinoma cells to enter a quiescent G0 state, cha

150 nd potent activity in sensitization of human colon carcinoma cells to FasL-induced apoptosis.

151 fectively modulate Fas function to sensitize colon carcinoma cells to FasL-induced apoptosis.

152 ective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis.

153 Exposure of HCT116 human colon carcinoma cells to reactive oxygen species, genera

154 We found that exposure of HT-29 human colon carcinoma cells to TNF for up to 20 days reduced t

155 shown that COX-2 inhibition sensitizes human colon carcinoma cells to tumor necrosis factor-related a

156 APK signaling inhibition in human breast and colon carcinoma cells using magnetic resonance spectrosc

157 hibition (GI50) value for batracylin in HT29 colon carcinoma cells was 10 micromol/L.

158 LoVo colon carcinoma cells were transfected with BCMO1 small

159 (shRNA)-mediated attenuation of ST6Gal-I in colon carcinoma cells with elevated endogenous expressio

160 Utilizing an isogenic panel of colon carcinoma cells with K-RAS or N-RAS variations, we

161 N null PC3 prostate and PIK3CA mutant HCT116 colon carcinoma cells with PI-103 resulted in a concentr

162 In HCT116 human colon carcinoma cells, 28c and 40f inhibited the Aurora-

163 strand breaks, activated DNA repair in human colon carcinoma cells, and effectively suppressed tumour

164 or cells, induce DNA damage and apoptosis in colon carcinoma cells, and reduce tumor size in animal m

165 ransport chain (ETC) in spermatogenic and in colon carcinoma cells, and silencing of either Fer or Fe

166 man wild-type p53- and p21-expressing HCT116 colon carcinoma cells, as well as in p53-null counterpar

167 used to deliver the doxorubicin to CT.26-WT colon carcinoma cells, eliciting a therapeutic response.

168 We show that in KM12C colon carcinoma cells, expression of kinase-deficient Sr

169 In colon carcinoma cells, Jerky facilitates Wnt signalling

170 In human colon carcinoma cells, Rgnef forms a complex with FAK an

171 When overexpressed in SW480 colon carcinoma cells, Sox17 represses beta-catenin/TCF

172 In human colon carcinoma cells, treatment with the Gli small-mole

173 ith cytoplasmic extracts of untreated HCT116 colon carcinoma cells, we identified the DEAD-box RNA he

174 etion was observed in both HT1080 and HCT116 colon carcinoma cells, where p21 was induced by DNA-dama

175 with CD44 immunopurified from LS174T or T84 colon carcinoma cells, which express primarily CD44v, ef

176 well as BaxBak double knockout HCT116 human colon carcinoma cells.

177 pregulate Fas expression in metastatic human colon carcinoma cells.

178 ctable by (1)H and (31)P MRS in prostate and colon carcinoma cells.

179 activity when combined with AZD7762 in human colon carcinoma cells.

180 arly S-phase, leading to cell death in human colon carcinoma cells.

181 e basis for its unique cytotoxic activity in colon carcinoma cells.

182 ses after intrasplenic/portal inoculation of colon carcinoma cells.

183 AP, Rap1GAP expression was silenced in human colon carcinoma cells.

184 pon DNA damage responses in human breast and colon carcinoma cells.

185 a in facilitating invasion and metastasis of colon carcinoma cells.

186 of macrophages to activate Wnt signaling in colon carcinoma cells.

187 cyclooxygenase-2/prostaglandin E(2) in HCA7 colon carcinoma cells.

188 al P-, but not E- or L-, selectin ligands on colon carcinoma cells.

189 cytotoxic activity in human osteosarcoma and colon carcinoma cells.

190 activation of PPARdelta up-regulated VEGF in colon carcinoma cells.

191 ted legume species towards MMP-9 activity in colon carcinoma cells.

192 matrix adhesion molecules in human SW480-ADH colon carcinoma cells.

193 ated kinases 1 and 2 (ERK1/2) in HT-29 human colon carcinoma cells.

194 reticulum retention sequence into GEO human colon carcinoma cells.

195 -MB-231, MCF-7 and Hs578T breast, and HCT116 colon carcinoma cells.

196 d CTL-mediated and FasL-induced apoptosis of colon carcinoma cells.

197 ed that 5-FU affects polyamine metabolism in colon carcinoma cells.

198 of colonic biopsy samples and polarized T84 colon carcinoma cells.

199 mouse on the growth of B16 melanoma or CT26 colon carcinoma cells.

200 linkage may mediate FAK activation in DLD-1 colon carcinoma cells.

201 arnessed to the reprogrammed mitochondria of colon carcinoma cells.

202 cell migration, as well as invasion of human colon carcinoma cells.

203 chanisms for hypoxic MYC inhibition in human colon carcinoma cells.

204 ice through intrasplenic inoculation of MC38 colon carcinoma cells.

205 and both MUC6 and MUC5AC expression in LS180 colon carcinoma cells.

206 anti-inflammatory effects in vitro using T84 colon carcinoma cells.

207 g and presentation assays in HeLa and murine colon carcinoma (CT26) cells showed that these inhibitor

208 Parent colon carcinoma (CT26) cells transduced with a large amo

209 aecalis across monolayers of polarized human colon carcinoma-derived T84 cells.

210 ransfusion inhibited growth of both lung and colon carcinoma ectopic tumors, whereas blockade of miR-

211 ll lymphoma, neuroblastoma, and prostate and colon carcinomas, either as a single agent or in combina

212 e Typhimurium sipA sopABDE2 mutant for human colon carcinoma epithelial (HT-29 and T84) cells and bov

213 The stromal cells within colon carcinoma express high levels of the platelet-deri

214 Although human colon carcinomas express TRAIL receptors, they can also

215 Resected, stage III colon carcinomas from patients (N = 2,686) randomly assi

216 ntial, revealing selectivity against HCT-15 (colon carcinoma) (GI50 approximately 74 mug/mL).

217 esquiterpenoid content; the IC(50) values on colon carcinoma, glioblastoma, and breast adenocarcinoma

218 intestinal epithelial cell line derived from colon carcinoma grown on semipermeable tissue culture in

219 survival in vitro, inhibits T-HEp3 and SW620 colon carcinoma growth in vivo.

220 Colon carcinoma HCT 116 cells were cultured and grown in

221 ved from extensive testing against the human colon carcinoma HCT-116 and the 60-cell-line panel at th

222 However, in the human colon carcinoma HCT-116 cell line, which is deficient in

223 amides A-C showed cytotoxicity against human colon carcinoma (HCT-116) cells with IC(50) values betwe

224 Here we show that human colon carcinoma (HCT-8) cells can exhibit a dissociative

225 Human colon carcinoma (HCT-8) cells show a stable transition f

226 n splicing at the genome-wide level in human colon carcinoma HCT116 and breast carcinoma MCF7 cells.

227 induced demethylation of CDKN2A promoter in colon carcinoma HCT116 cells and its reactivation after

228 n, we tested TOP1mt KO fibroblasts and human colon carcinoma HCT116 cells and measured mtDNA after 3-

229 mosome instability induced in cultured human colon carcinoma HCT116 cells by the antitumor radiomimet

230 5-Fluorouracil treatment of colon carcinoma HCT116 cells expressing WT p53 results i

231 In human colon carcinoma HCT116 cells with wild-type (wt) p53, ga

232 ntly elevated in DNMT1-/- or DNMT3B-/- human colon carcinoma (HCT116) cells.

233 After a short dose of camptothecin in human colon carcinoma HT29 cells, DNA replication was inhibite

234 ession is seen in some poorly differentiated colon carcinomas in humans.

235 Using Colo205 human colon carcinomas in nude mice as a model, we found that

236 egrin enhances the tumorigenic properties of colon carcinoma, including activation of autocrine TGF-b

237 stable overexpression in Ras-induced murine colon carcinomas increased microvascular densities and v

238 The recently cloned colon carcinoma kinase 4 (CCK4) oncogene contains an evo

239 is more stable than the interactions of the colon carcinoma kinase 4 transmembrane domain.

240 e kinase superfamily initially identified as colon carcinoma kinase-4, is highly expressed in various

241 Moreover, in the various RAS mutant colon carcinoma lines, the transforming growth factor-al

242 For CT26 colon carcinoma liver metastases, inhibition of both VEG

243 T6Gal-I, a feature that is characteristic of colon carcinoma, may confer tumor cells with a selective

244 145 and LNCaP (prostate carcinoma), HCT-116 (colon carcinoma), MCF-7 (breast carcinoma) and NCI-H460

245 Three cell lines were employed: DLD1 (human colon carcinoma), MCF7 (human breast carcinoma) and NCI/

246 ications (PTMs), in the layers of the HCT116 colon carcinoma MCTS.

247 with ulcerative colitis and tumors including colon carcinoma, melanoma, hepatic carcinoma, ovarian ca

248 ble target for therapeutics aimed at curbing colon carcinoma metastasis.

249 itabine and vorinostat cooperate to suppress colon carcinoma metastasis.

250 t are required for cachexia in the mouse C26 colon carcinoma model of cancer.

251 Using a transplantable colon carcinoma model, we found that CD8(+) T cells beca

252 murine hepatocellular and colitis-associated colon carcinoma models, and this was associated with red

253 ty against both the L1210 leukemia and CT-26 colon carcinoma models.

254 udies identify Rgnef as a novel regulator of colon carcinoma motility and invasion, and they show tha

255 ) imaging mass spectrometry (IMS) in HCT 116 colon carcinoma multicellular spheroids to assess the di

256 okines in a clinical cohort of patients with colon carcinoma (n = 378).

257 location were determined in stage II and III colon carcinomas (n = 160) and normal mucosa (n = 25) by

258 ermined in patients with TNM stage II or III colon carcinomas (n = 2,693) who participated in randomi

259 In a mouse xenograft model of human colon carcinoma, nal-IRI dosing could achieve higher int

260 However, human colon carcinoma often deregulates the Fas signaling path

261 n HHD model in which HLA-A2(neg) tumor (MC38 colon carcinoma or B16 melanoma) cells are not recognize

262 When injected i.v. in mice bearing CT26 colon carcinoma or B16 melanoma, the 4PD nanoparticles p

263 The LIM 1863 colon carcinoma organoid undergoes epithelial-mesenchyma

264 In colon carcinoma patients, the contingent of circulating

265 they show that a Rgnef-FAK linkage promotes colon carcinoma progression in vivo.

266 comparatively investigated their effects on colon carcinoma proliferation, a) in vitro against colon

267 t CD44v is a functional P-selectin ligand on colon carcinoma provides a novel perspective on the enha

268 lso to other tumor types, including lung and colon carcinomas regardless of their BRAF status.

269 ability of human T lymphocytes to infiltrate colon carcinoma remain unclear.

270 mice bearing 4T1 mammary carcinoma and MC38 colon carcinoma, respectively.

271 Human colon carcinoma (RKO36), mouse sarcoma (SA-NH), along wi

272 types of cancers (e.g., breast carcinoma and colon carcinoma), S664-pTSC2 seemed to be a more sensiti

273 te that expression of CD103/beta(7) in human colon carcinoma-specific CTL is synergistically enhanced

274 es, exerts growth inhibitory effects against colon carcinoma, suggesting a nutraceutical potential in

275 (MEF2C), tumor suppressor pathway (p53) and colon carcinoma survival (beta-catenin).

276 er a human Kaposi's sarcoma (SLK) or a human colon carcinoma (SW1222).

277 50 muM against Cisplatin-Resistant SKOV3 and colon carcinoma SW480 cell lines.

278 In the CT26 mouse model of colon carcinoma, therapeutic vaccination with a lead Psi

279 n of smMLCK decreased (19.5 +/- 4.7 fold) in colon carcinoma tissues compared to normal colon tissues

280 We used a spheroid model of colon carcinoma to analyze integrin dynamics as a functi

281 sifies the human protein encoded by immature colon carcinoma transcript-1 (ICT1) as one of a family o

282 ry tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy.

283 therapeutic potential in an immunocompetent colon carcinoma tumor model.

284 ith the TSA mammary adenocarcinoma and MCA38 colon carcinoma tumor models that show little response t

285 When syngeneic murine CT26 colon carcinoma tumors (BALB/c) and B16 melanoma and Lew

286 and edema in the invasive areas of CT26.CL25 colon carcinoma tumors as shown by CD31 IHC.

287 d orally, mastic oil inhibited the growth of colon carcinoma tumors in mice.

288 mic imbalances of chromosome 8 in 51 primary colon carcinomas using a custom-designed genomic array c

289 was measured in arthritic ankles and in CT26 colon carcinomas when the mice breathed oxygen and were

290 ls: mouse hepatocellular carcinoma and human colon carcinoma, whereby the metabolism has been profile

291 CaSR expression was weak in colon carcinomas with a more-differentiated histologic p

292 is essential for both SLK sarcoma and SW1222 colon carcinoma xenograft growth.

293 re, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXRalpha-de

294 nd robust in vivo efficacy in human lung and colon carcinoma xenograft models.

295 ses as well as growth of subcutaneous HCT116 colon carcinoma xenograft tumors, without affecting body

296 acy studies it inhibited the growth of SW620 colon carcinoma xenografts following oral administration

297 sly that the endothelium of vessels in human colon carcinoma xenografts in mice is a mosaic structure

298 of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice.

299 og on the tumor growth of NTR1-positive HT29 colon carcinoma xenografts.

300 presses the growth of human glioblastoma and colon carcinoma xenografts.